Core Viewpoint - Sino Medical (688108) has received regulatory measures from Tianjin Securities Regulatory Bureau due to inaccuracies in financial disclosures, specifically related to accounting errors that led to a misstatement of investment income and net profit [1][2] Group 1: Regulatory Actions - The Tianjin Securities Regulatory Bureau issued a decision requiring Sino Medical to correct its financial disclosures and imposed regulatory talks on Chairman Sun Jianhua and CFO Shen Lihua for their lack of diligence [2] - Sino Medical acknowledges the issues raised in the regulatory decision and commits to internal accountability, enhancing financial management, and improving information disclosure quality to prevent future violations [2] Group 2: Financial Performance - For the first half of 2025, Sino Medical reported total revenue of 240 million yuan, a year-on-year increase of 12.53%, driven by a 17.40% growth in coronary intervention business revenue due to increased sales of newly included products [3] - The company achieved a total profit of 23.01 million yuan, a significant increase of 585.93% compared to the previous year, attributed to revenue growth and a decrease in sales and R&D expenses [3] - The net profit attributable to shareholders was 13.84 million yuan, reflecting a 296.54% increase year-on-year, influenced by the substantial rise in total profit and a 299.98% increase in income tax expenses [3]

证券代码：688108 证券简称：赛诺医疗 公告编号：2025-044 赛诺医疗科学技术股份有限公司 关于收到天津证监局行政监管措施决定书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 赛诺医疗科学技术股份有限公司（以下简称"赛诺医疗""公司"）于 2025 年 9 月 4 日收到中国证券监督管理委员会天津监管局（以下简称"天津证监局"）出具的《关于 对赛诺医疗科学技术股份有限公司采取责令改正及对孙箭华、沈立华采取监管谈话措施的 决定》（津证监措施〔2025)27 号）（以下简称《决定书》），现将有关情况公告如下： 一、《决定书》相关内容 赛诺医疗科学技术股份有限公司、孙箭华、沈立华: 根据《上市公司信息披露管理办法》（证监会令第 182 号）第五十一条第三款、第五 十二条规定，现决定对赛诺医疗采取责令改正的行政监管措施，对孙箭华、沈立华采取监 管谈话的行政监管措施。公司及相关人员应认真吸取教训，严肃组织开展公司内部追责， 加强财务管理和内部控制，提高规范运作水平，杜绝此类违规行为再次发生。你公司应于 收到本决定 ...

Core Viewpoint - Sino Medical (688108) has shown a significant increase in stock price and trading volume, indicating positive market sentiment and potential investment interest [1][2]. Group 1: Stock Performance - As of September 3, 2025, Sino Medical's stock closed at 36.28 yuan, up 12.67% with a trading volume of 750,100 hands and a total transaction amount of 2.57 billion yuan [1]. - The net inflow of main funds was 215 million yuan, accounting for 8.38% of the total transaction amount, while retail investors experienced a net outflow of 78.528 million yuan, representing 3.06% of the total [1][2]. Group 2: Recent Fund Flow - Over the past five days, the stock has experienced fluctuations in fund flow, with notable net inflows and outflows from different investor categories [2]. - On September 2, 2025, the stock saw a net outflow of main funds amounting to 183 million yuan, while retail investors had a net inflow of 66.872 million yuan [2]. Group 3: Financing and Margin Trading - On September 3, 2025, the financing buy amounted to 341 million yuan, while financing repayment was 398 million yuan, resulting in a net repayment of 57.312 million yuan [3]. - The total margin trading balance stood at 928 million yuan, with a margin balance of 0.73 million yuan [3]. Group 4: Company Financials - Sino Medical reported a main revenue of 240 million yuan for the first half of 2025, a year-on-year increase of 12.53%, and a net profit of 13.8416 million yuan, up 296.54% [5]. - The company's gross profit margin was 63.64%, significantly higher than the industry average of 51.85% [5]. Group 5: Industry Comparison - Sino Medical's total market capitalization is 15.094 billion yuan, which is above the industry average of 11.994 billion yuan, ranking 22nd in the industry [5]. - The company has a price-to-earnings ratio of 545.25, which is considerably higher than the industry average of 65.28, indicating a potential overvaluation [5].

Market Performance - The Sci-Tech Innovation Board (STAR Market) index fell by 1.64%, closing at 1306.48 points, with a total trading volume of 5.041 billion shares and a turnover of 235.696 billion yuan, resulting in an average turnover rate of 2.70% [1] - Among the tradable stocks on the STAR Market, 146 stocks closed higher, with 9 stocks rising over 10% and 14 stocks rising between 5% and 10%. Conversely, 440 stocks closed lower, with 6 stocks declining over 10% [1] Stock Turnover Rates - The distribution of turnover rates shows that 27 stocks had turnover rates between 10% and 20%, 95 stocks between 5% and 10%, 137 stocks between 3% and 5%, 277 stocks between 1% and 3%, and 53 stocks had turnover rates below 1% [1] - The stock with the highest turnover rate was Ying Shi Innovation, which closed down by 2.26% with a turnover rate of 18.84% and a transaction amount of 2.047 billion yuan. Following it was Sainuo Medical, which closed up by 12.67% with a turnover rate of 18.03% and a transaction amount of 2.570 billion yuan [1] Sector Analysis - Among stocks with a turnover rate exceeding 5%, the electronics sector had the most stocks, with 45 stocks listed. The power equipment and computer sectors followed with 15 and 14 stocks, respectively [2] - In terms of capital flow, 47 stocks with high turnover rates saw net inflows from main funds, with the highest net inflows recorded for Yuanjie Technology, Sainuo Medical, and Artis, amounting to 292 million yuan, 205 million yuan, and 148 million yuan, respectively [2] Leverage Fund Movements - A total of 77 stocks with high turnover rates recently received net purchases from leveraged funds. Notably, Baiji Shenzhou, Huahong Company, and Shangwei New Materials saw significant increases in financing balances of 673 million yuan, 451 million yuan, and 322 million yuan, respectively [2]

Market Overview - On September 3, the medical device sector declined by 0.57%, with Huqiang Technology leading the drop [1] - The Shanghai Composite Index closed at 3813.56, down 1.16%, while the Shenzhen Component Index closed at 12472.0, down 0.65% [1] Top Performers - Sino Medical (688108) saw a significant increase of 12.67%, closing at 36.28 with a trading volume of 750,100 shares and a transaction value of 2.57 billion [1] - Other notable gainers included: - Sanyou Medical (688085) up 7.76% to 25.70 [1] - Kangtuo Medical (688314) up 5.59% to 38.36 [1] - Rejing Bio (688068) up 5.07% to 196.26 [1] - New Industry (300832) up 4.08% to 64.82 [1] Underperformers - Huqiang Technology (688151) experienced the largest decline of 8.44%, closing at 21.48 with a trading volume of 73,900 shares and a transaction value of 164 million [2] - Other significant decliners included: - Jimin Health (603222) down 8.16% to 10.47 [2] - Aomei Medical (002950) down 4.70% to 9.73 [2] - Boxin Bio (836504) down 4.53% to 28.68 [2] Capital Flow - The medical device sector saw a net outflow of 271 million from institutional investors and 266 million from speculative funds, while retail investors contributed a net inflow of 537 million [2][3] - Notable capital flows included: - Sino Medical with a net inflow of 215 million from institutional investors [3] - Huqiang Technology with a net outflow of 1.37 billion from speculative funds [3] - Huatai Medical (688617) had a net inflow of 107 million from institutional investors [3]

Market Overview - The Shanghai Composite Index closed at 3814.20 points, below the five-day moving average, with a decline of 1.14% [1] - The total trading volume of A-shares reached 1,878.28 billion yuan [1] Stocks Performance - A total of 139 A-shares broke through the five-day moving average today [1] - Stocks with significant deviation rates include: - Hailianxun (300277) with a deviation rate of 14.15%, closing up 20.03% [1] - Shoukai Co. (600376) with a deviation rate of 7.01%, closing up 9.85% [1] - Zhongchen Technology (603275) with a deviation rate of 6.97%, closing up 9.99% [1] - Other notable stocks with smaller deviation rates include: - Yunda Co. (300409) with a deviation rate of 6.32%, closing up 10.92% [1] - Hanzhong Precision (002158) with a deviation rate of 6.30%, closing up 10.00% [1] Detailed Stock Data - The following table summarizes the performance of selected stocks that broke through the five-day moving average: | Stock Code | Stock Name | Daily Change (%) | Turnover Rate (%) | Five-Day MA (yuan) | Latest Price (yuan) | Deviation Rate (%) | | --- | --- | --- | --- | --- | --- | --- | | 300277 | Hailianxun | 20.03 | 24.96 | 13.54 | 15.46 | 14.15 | | 600376 | Shoukai Co. | 9.85 | 6.33 | 2.71 | 2.90 | 7.01 | | 603275 | Zhongchen Technology | 9.99 | 10.43 | 50.42 | 53.94 | 6.97 | | 002067 | Jingxing Paper | 10.00 | 15.98 | 4.34 | 4.62 | 6.55 | | 300409 | Yunda Co. | 10.92 | 20.47 | 22.07 | 23.47 | 6.32 | | 002158 | Hanzhong Precision | 10.00 | 3.58 | 25.04 | 26.62 | 6.30 | | 688108 | Sainuo Medical | 9.10 | 11.70 | 33.29 | 35.13 | 5.54 | | 603283 | Saiteng Co. | 7.32 | 9.18 | 41.65 | 43.85 | 5.27 | | 300655 | Jingrui Materials | 7.83 | 14.56 | 12.30 | 12.94 | 5.24 | | 300905 | Baolidai | 9.29 | 12.54 | 32.92 | 34.57 | 5.02 | | 603992 | Songlin Technology | 6.80 | 1.51 | 29.63 | 31.10 | 4.98 | | 688717 | Ailuo Energy | 9.04 | 5.60 | 68.52 | 71.80 | 4.78 | | 002549 | Kaimeteqi | 8.68 | 17.83 | 16.53 | 17.28 | 4.52 | | 603367 | Chenxin Pharmaceutical | 10.02 | 5.75 | 25.75 | 26.90 | 4.45 | | 301491 | Hansang Technology | 6.43 | 26.20 | 66.30 | 69.07 | 4.18 | | 300303 | Jufei Optoelectronics | 5.04 | 10.31 | 6.84 | 7.08 | 3.48 | | 601869 | Changfei Optical Fiber | 10.00 | 5.24 | 88.00 | 91.06 | 3.47 | | 600699 | Junsheng Electric | 4.33 | 6.13 | 21.26 | 21.95 | 3.26 | | 002531 | Tienswind Energy | 5.37 | 2.16 | 6.86 | 7.07 | 3.03 | | 301182 | Kaiwang Technology | 6.37 | 9.05 | 38.56 | 39.73 | 3.02 [2]

Group 1 - The medical device sector experienced a decline of 1.78% on September 2, with Jimin Health leading the losses [1] - The Shanghai Composite Index closed at 3858.13, down 0.45%, while the Shenzhen Component Index closed at 12553.84, down 2.14% [1] - Notable gainers in the medical device sector included Wende Biological, which rose by 7.61% to a closing price of 25.58, and Jinhao Medical, which increased by 6.66% to 29.48 [1] Group 2 - Jimin Health saw a significant drop of 10.02%, closing at 11.40, with a trading volume of 1.0859 million shares and a transaction value of 1.331 billion [2] - Other notable decliners included Rejing Biological, which fell by 8.72% to 186.79, and Yikang Haosheng, which decreased by 7.71% to 34.24 [2] - The medical device sector experienced a net outflow of 1.23 billion from major funds, while retail investors contributed a net inflow of 1.011 billion [2]

"天津辖区上市公司 2025 年投资者网上集体接待日 证券代码：688108 证券简称：赛诺医疗 公告编号：2025-043 赛诺医疗科学技术股份有限公司关于参加 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）；或关注微信公众号（名称：全景财经）；或下载全景路 演 APP，参与本次互动交流。活动时间为 2025 年 9 月 11 日（周四）15:00-17:00。 出席本次活动的有公司董事长、总经理孙箭华先生，公司董事、财务总监沈 立华女士，公司董事、董事会秘书黄凯先生，公司独立董事马元驹先生、高岩先 生、李蕊女士（如有特殊情况，出席人员会有调整），届时，公司高管将在线就 公司 2025 半年度业绩、公司治理、发展战略、经营状况等投资者关心的问题， 与投资者进行沟通与交流，欢迎广大投资者踊跃参与！ 特此公告。 赛诺医疗科学技术股份有限公司董事会 2025 年 9 月 02 日 暨半年报业绩说明会"活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为进一步加 ...

（文章来源：每日经济新闻） 赛诺医疗（688108.SH）9月1日在投资者互动平台表示，公告自膨式颅内药物涂层支架系统目前正在注 册过程中，公司尚无法预测其后续上市后的业绩情况。 每经AI快讯，有投资者在投资者互动平台提问：在公司中报中提到"自膨式颅内药物涂层支架系统"在 2025年获得上市批准，我想问一下要是后续该产品上市了，预计会给公司带来多少营收以及利润呢？ ...

Group 1 - The stock exchange monitors trading behavior of stocks that exhibit significant abnormal fluctuations within 10 trading days after such events occur, particularly focusing on large buy or sell orders within a one-minute timeframe [1] Group 2 - A list of stocks under abnormal fluctuation monitoring includes: - Kaipu Cloud: Monitoring from September 1, 2025, to September 12, 2025, with abnormal activity starting on August 25, 2025 - *ST Gao Hong: Monitoring from August 26, 2025, to September 8, 2025, with undisclosed abnormal activity start date - Siquan New Materials: Monitoring from August 22, 2025, to September 4, 2025, with undisclosed abnormal activity start date - *ST Su Wu: Monitoring from August 21, 2025, to September 3, 2025, with undisclosed abnormal activity start date - Sano Medical: Monitoring from August 19, 2025, to September 1, 2025, with abnormal activity starting on August 7, 2025 [2][3]